Method: Participants with a history of genotypic/phenotypic drug resistance to
protease inhibitors (
PIs) or with HIV-1 genotypic drug resistance to
PIs at baseline (including
D30N,
M46I/L,
I47V/A,
G48V,
I50L,
I54M/L,
Q58E,
T74P,
L76V,
V82A/F/L/T/S,
N83D,
I84V,
N88S, or
L90M) were excluded, despite any reported effects of
PI resistance or resistance